Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18320297 | 0.79 | NAMPT (0.38) | NAMPTCNR2CYP1A2CA2CHKA | |
| SCHEMBL9978112 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL20135742 | 0.77 | NAMPT (0.37) | NAMPTCNR2CYP1A2CA2CHKA | |
| Trifluoroacetic Acid SCHEMBL31579460 | 0.75 | NAMPT (0.34) | NAMPTJAK1SOS1SOS2 | |
| SCHEMBL15286428 | 0.73 | JAK3 (0.46) | NAMPT | |
| SCHEMBL700399 | 0.73 | NAMPT (0.41) | NAMPTCNR2CYP1A2CA2CHKA | |
| SCHEMBL799357 | 0.72 | SOS1 (0.35) | SOS1SOS2 | |
| Hydrochloric Acid SCHEMBL15288269 | 0.72 | JAK3 (0.45) | NAMPT | |
| SCHEMBL30875892 | 0.72 | NAMPT (0.40) | NAMPTCNR2CYP1A2CA2CHKA | |
| SCHEMBL22208191 | 0.72 | EPHX1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | NAMPT 20/4885CNR2 3540/4885CYP1A2 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.